This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Subramaniam, D. Articles by Anant, S. Search for Related Content PubMed PubMed Citation Articles by Subramaniam, D. Articles by Anant, S.

Diphenyl Difluoroketone: A Curcumin Derivative with Potent In vivo Anticancer Activity

¹ Section of Digestive Diseases and Nutrition, Department of Medicine and ² Department of Cell Biology, University of Oklahoma Health Sciences Center; ³ Swaasth, Inc., Oklahoma City, Oklahoma; ⁴ Division of Gastroenterology, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, Missouri; ⁵ Dorothy M. Davis Heart and Lung Research Institute, Ohio State University Medical Center, Columbus, Ohio; and ⁶ Institute of Organic and Medicinal Chemistry, University of Pecs, Pecs, Hungary

Requests for reprints: Shrikant Anant, Section of Digestive Diseases and Nutrition, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73126. Fax: 405-271-5450; E-mail: shrikant-anant{at}ouhsc.edu.

Key Words: Novel • Signaling • Therapeutics

Diphenyl difluoroketone (EF24), a molecule having structural similarity to curcumin, was reported to inhibit proliferation of a variety of cancer cells in vitro. However, the efficacy and in vivo mechanism of action of EF24 in gastrointestinal cancer cells have not been investigated. Here, we assessed the in vivo therapeutic effects of EF24 on colon cancer cells. Using hexosaminidase assay, we determined that EF24 inhibits proliferation of HCT-116 and HT-29 colon and AGS gastric adenocarcinoma cells but not of mouse embryo fibroblasts. Furthermore, the cancer cells showed increased levels of activated caspase-3 and increased Bax to Bcl-2 and Bax to Bcl-xL ratios, suggesting that the cells were undergoing apoptosis. At the same time, cell cycle analysis showed that there was an increased number of cells in the G₂-M phase. To determine the effects of EF24 in vivo, HCT-116 colon cancer xenografts were established in nude mice and EF24 was given i.p. EF24 significantly suppressed the growth of colon cancer tumor xenografts. Immunostaining for CD31 showed that there was a lower number of microvessels in the EF24-treated animals coupled with decreased cyclooxygenase-2, interleukin-8, and vascular endothelial growth factor mRNA and protein expression. Western blot analyses also showed decreased AKT and extracellular signal-regulated kinase activation in the tumors. Taken together, these data suggest that the novel curcumin-related compound EF24 is a potent antitumor agent that induces caspase-mediated apoptosis during mitosis and has significant therapeutic potential for gastrointestinal cancers. [Cancer Res 2008;68(6):1962–9]

This article has been cited by other articles:

				D. Subramaniam, P. Giridharan, N. Murmu, N. P. Shankaranarayanan, R. May, C. W. Houchen, R. P. Ramanujam, A. Balakrishnan, R. A. Vishwakarma, and S. Anant Activation of Apoptosis by 1-Hydroxy-5,7-Dimethoxy-2-Naphthalene-Carboxaldehyde, a Novel Compound from Aegle marmelos Cancer Res., October 15, 2008; 68(20): 8573 - 8581. [Abstract] [Full Text] [PDF]